A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Dasatinib
Related studies linked through entity extraction aliases.
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
- Status
- WITHDRAWN
- Phase
- PHASE2
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans
- Status
- COMPLETED
- Phase
- PHASE2
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
- Status
- COMPLETED
- Phase
- PHASE1
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
- Status
- UNKNOWN
- Phase
- PHASE4
Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Dasatinib In Waldenström Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE1
Frontline Asciminib Combination in Chronic Phase CML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
- Status
- COMPLETED
- Phase
- N/A
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Status
- TERMINATED
- Phase
- PHASE1
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
- Status
- RECRUITING
- Phase
- PHASE4
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- Status
- RECRUITING
- Phase
- PHASE1
Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment
- Status
- UNKNOWN
- Phase
- PHASE2
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
- Status
- WITHDRAWN
- Phase
- PHASE1
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2